{"id":828814,"date":"2025-03-24T07:16:31","date_gmt":"2025-03-24T11:16:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/"},"modified":"2025-03-24T07:16:31","modified_gmt":"2025-03-24T11:16:31","slug":"biolinerx-to-report-2024-annual-results-on-march-31-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/","title":{"rendered":"BioLineRx to Report 2024 Annual Results on March 31, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Management to Hold Conference Call at <span class=\"xn-chron\">8:30 a.m. EDT<\/span><\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">TEL AVIV, Israel<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 24, 2025<\/span><\/span> \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended <span class=\"xn-chron\">December 31, 2024<\/span> on <span class=\"xn-chron\">Monday, March 31, 2025<\/span>, before the U.S. markets open.<\/p>\n<p>\u00a0<\/p>\n<div id=\"prni_dvprnejpgd7f1left\" dir=\"ltr\" style=\"width: 100%;text-align: left\">\n        <img decoding=\"async\" id=\"prnejpgd7f1left\" style=\"width: 400px;height: 107px\" title=\"BioLineRx_Ltd_Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" alt=\"BioLineRx_Ltd_Logo\" align=\"middle\" \/>\n      <\/div>\n<p>The Company will host a conference call at <span class=\"xn-chron\">8:30 a.m. EDT<\/span> featuring remarks by <span class=\"xn-person\">Philip Serlin<\/span>, Chief Executive Officer.<\/p>\n<p>To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the <a href=\"https:\/\/ir.biolinerx.com\/events\/event-details\/biolinerx-report-2024-annual-results-march-31-2025\" target=\"_blank\" rel=\"nofollow\">event page<\/a>\u00a0on the Company&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the call will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until <span class=\"xn-chron\">April 2, 2025<\/span>; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.<\/p>\n<p>\n        <b>About BioLineRx<\/b>\n      <\/p>\n<p>BioLineRx Ltd. (NASDAQ\/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases.\u00a0The company&#8217;s first approved product is APHEXDA\u00ae (motixafortide) with an indication in the U.S. for stem cell mobilization for\u00a0autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding <span class=\"xn-location\">Asia<\/span>) and Gloria Biosciences (in <span class=\"xn-location\">Asia<\/span>).\u00a0BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.<\/p>\n<p>Learn more about who we are, what we do, and how we do it at\u202f<a href=\"http:\/\/www.biolinerx.com\/\" target=\"_blank\" rel=\"nofollow\">www.biolinerx.com<\/a>, or on\u202f<a href=\"https:\/\/twitter.com\/BioLineRx_Ltd\" target=\"_blank\" rel=\"nofollow\">Twitter<\/a>\u202fand\u202f<a href=\"https:\/\/www.linkedin.com\/company\/112275\/admin\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.\u202f\u00a0and events.<\/p>\n<p>\n        <b>CONTACTS:<\/b>\n      <\/p>\n<p>\n        <u><br \/>\n          <span class=\"xn-location\">United States<\/span><br \/>\n        <\/u> \u00a0 \u00a0\u00a0 <br \/><span class=\"xn-person\">Irina Koffler<\/span><br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:ikoffler@lifesciadvisors.co\" target=\"_blank\" rel=\"nofollow\">ikoffler@lifesciadvisors.com<\/a><\/p>\n<p>\n        <u><br \/>\n          <span class=\"xn-location\">Israel<\/span><br \/>\n          <br \/>\n        <\/u><br \/>\n        <span class=\"xn-person\">Moran Meir<\/span><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:moran@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">moran@lifesciadvisors.com<\/a><\/p>\n<p>Logo: <a href=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO47914&amp;sd=2025-03-24\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-2024-annual-results-on-march-31-2025-302409115.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-2024-annual-results-on-march-31-2025-302409115.html<\/a><\/p>\n<p>SOURCE  BioLineRx Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO47914&amp;Transmission_Id=202503240700PR_NEWS_USPR_____IO47914&amp;DateId=20250324\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open. \u00a0 The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page\u00a0on the Company&#8217;s website. Please allow &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioLineRx to Report 2024 Annual Results on March 31, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828814","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open. \u00a0 The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page\u00a0on the Company&#8217;s website. Please allow &hellip; Continue reading &quot;BioLineRx to Report 2024 Annual Results on March 31, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T11:16:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioLineRx to Report 2024 Annual Results on March 31, 2025\",\"datePublished\":\"2025-03-24T11:16:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/\"},\"wordCount\":350,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/\",\"name\":\"BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"datePublished\":\"2025-03-24T11:16:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-2024-annual-results-on-march-31-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioLineRx to Report 2024 Annual Results on March 31, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/","og_locale":"en_US","og_type":"article","og_title":"BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk","og_description":"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open. \u00a0 The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page\u00a0on the Company&#8217;s website. Please allow &hellip; Continue reading \"BioLineRx to Report 2024 Annual Results on March 31, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-24T11:16:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioLineRx to Report 2024 Annual Results on March 31, 2025","datePublished":"2025-03-24T11:16:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/"},"wordCount":350,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/","name":"BioLineRx to Report 2024 Annual Results on March 31, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","datePublished":"2025-03-24T11:16:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-2024-annual-results-on-march-31-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioLineRx to Report 2024 Annual Results on March 31, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828814"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828814\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}